Schizophrenia Research
Volume 86, Issue 1 , Pages 30-35 , September 2006

Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia

  • Xiaoduo Fan

      Affiliations

    • Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States
    • Corresponding Author InformationCorresponding author. Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, United States. Tel.: +1 617 912 7800; fax: +1 617 912 7820.
    • ,
  • Emily Liu

      Affiliations

    • Division of Endocrinology, Women and Children's Hospital of Buffalo, Buffalo, NY, United States
    • School of Medicine and Biological Sciences, State University of New York at Buffalo, Buffalo, NY, United States
    • ,
  • Cynthia Pristach

      Affiliations

    • School of Medicine and Biological Sciences, State University of New York at Buffalo, Buffalo, NY, United States
    • Department of Psychiatry, Erie County Medical Center, Buffalo, NY, United States
    • ,
  • Donald C. Goff

      Affiliations

    • Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States
    • ,
  • David C. Henderson

      Affiliations

    • Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States

Received 9 December 2005 ,Revised 11 April 2006 ,Accepted 17 April 2006.

References 

  1. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29:1326–1334
  2. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 1998;800:125–135
  3. Birch NP, Christie DL, Renwick AG. Immunoreactive insulin from mouse brain cells in culture and whole rat brain. Biochem. J. 1984;218:19–27
  4. Boyd FT, Clarke DW, Muther TF, Raizada MK. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J. Biol. Chem. 1985;260:15880–15884
  5. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry. 1999;56:1135–1140
  6. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J. Clin. Psychopharmacol. 2002;22:244–251
  7. Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 1994;269:8445–8454
  8. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000;26:903–912
  9. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, et al. Olanzapine induces insulin resistance: results from a prospective study. J. Clin. Psychiatry. 2003;64:1436–1439
  10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  11. Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol. Psychiatry. 1991;30:1219–1228
  12. Harrison G, Croudace T, Mason P, Glazebrook C, Medley I. Predicting the long-term outcome of schizophrenia. Psychol. Med. 1996;26:697–705
  13. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 1978;272:827–829
  14. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry. 2003;64:575–579
  15. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry. 2005;62:19–28
  16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  17. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 2001;74:270–280
  18. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry. 1992;149:689–690
  19. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J. Clin. Psychiatry. 2003;64:316–320
  20. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry. 1992;149:68–72
  21. Lozovsky DB, Kopin IJ, Saller CF. Modulation of dopamine receptor supersensitivity by chronic insulin: implication in schizophrenia. Brain Res. 1985;343:190–193
  22. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80:19–32
  23. McGlashan TH. The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study. Arch. Gen. Psychiatry. 1986;43:167–176
  24. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry. 2000;61:742–749
  25. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr. Res. 2003;59:19–27
  26. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005;80:9–18
  27. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2003;163:427–436
  28. Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J. Clin. Exp. Psychopathol. 1959;20:53–57
  29. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry. 2005;66:559–563
  30. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry. 2002;159:561–566
  31. Singh MM, De Dios LV, Kline NS. Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics. 1970;11:562–570
  32. Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989;31:143–157
  33. Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, et al. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature. 1997;388:686–690
  34. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101–123
  35. Woods SC, Porte D, Bobbioni E, Ionescu E, Sauter JF, Rohner-Jeanrenaud F, et al. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. Am. J. Clin. Nutr. 1985;42:1063–1071
  36. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 2001;177:125–134

PII: S0920-9964(06)00177-0

doi: 10.1016/j.schres.2006.04.010

Schizophrenia Research
Volume 86, Issue 1 , Pages 30-35 , September 2006

Article Tools

* Image Usage & Resolution